An innovative, internationally operating pharmaceutical company, headquartered in Latvia, part of Northern Europe.
Founded in 1946 Grindeks celebrates 75th anniversary in 2021. Today we are the leading pharmaceutical manufacturer in the Baltic States, headquartered in Riga, Latvia. Over the years we have been recognized for helping millions of patients worldwide.
Our products are sold in 90 countries globally. The most important export markets of Grindeks are the EU countries, Russia and other CIS countries, the USA, Canada and Japan.
Grindeks product portfolio is successfully composed of original products, generics and active pharmaceutical ingredients, all produced in line with the world-class requirements of safety and quality. To help people overcome the health issues, we focus on the heart and cardiovascular, CNS, anti-cancer and anti-diabetes medicines. We aim to improve people lives and make health solutions accessible to our patients.
Over the years Grindeks has grown into the world-class pharmaceutical company. Today Grindeks Group consists of JSC Grindeks and its four subsidiaries. Each one of them is contributing to the growth of the Group and being an integral part of the corporation.
JSC Kalceks based in Latvia, is one of the oldest pharmaceutical companies in the Baltic states, specializing in generics mostly for the hospital segment. HBM Pharma Ltd., based in Slovakia, is a pharmaceutical product manufacturer and operates in the field of producing injectable in ampules and tablets. JSC Tallinn Pharmaceutical Plant, based in Estonia, produces ointments, in turn, Namu apsaimniekosanas projekti Ltd. is responsible for managing Grindeks real estate.
Our branches and representative offices are present in 11 countries: Lithuania, Estonia, Belarus, Ukraine, Azerbaijan, Georgia, Uzbekistan, Moldova, Kazakhstan, Armenia, Kyrgyzstan.